Michael Zbinovec

• 
  www.pharmabusiness.com/News/index.cfm?articleid=498222& - [Cached Version]
  Published on: 12/6/2007    Last Visited: 12/6/2007  

  Michael Zbinovec, +1-312-368-3164, Chicago

• 
  www.mcbcommunications.com/Articles/merck20050822.shtml - [Cached Version]
  Published on: 8/22/2005    Last Visited: 3/1/2008  

  "The industry has learned from the Wyeth fen-phen litigationto fight it tooth and nail," said Michael Zbinovec, apharmaceutical analyst at Fitch Ratings in Chicago.In the Atlantic City case, Humeston, a Purple Heart recipient,says he took the drug for pain in his knees, one of which heinjured in Vietnam.

• 
  www.smartbrief.com/news/aaaa/industryBW-detail.jsp?id=0 - [Cached Version]
  Published on: 10/6/2008    Last Visited: 5/20/2008  

  Michael Zbinovec, +1-312-368-3164 (Chicago)

• 
  Cambridge BioPartners | Press| Jun. 5--By day he is... - [Cached Version]
  Published on: 6/6/2005    Last Visited: 6/28/2008  

  "Over the last five to eight years, they've done a good job focusing their R&D and looking at their early-stage pipeline that could develop into blockbusters," said Michael Zbinovec, an analyst at Fitch Ratings in Chicago.

• 
  Capital Investment | Winning the Pharma Cap Spending... - [Cached Version]
  Published on: 11/6/2006    Last Visited: 11/6/2006  

  "Pharma's been talking about cutting back on spending for the last few years," says Michael Zbinovec, director of corporate finance at Fitch Ratings (Chicago), who specializes in health care."Any time you have fewer facilities, you have less spending."As part of his research, Zbinovec talks to a large number of equipment suppliers.This year, he says, more pharma spending appears to be covering outsourcing, rather than new equipment purchases.

• 
  Dallas Morning News | News for Dallas, Texas | Business - [Cached Version]
  Published on: 8/22/2005    Last Visited: 8/22/2005  

  "The industry has learned from the Wyeth fen-phen litigation to fight it tooth and nail," said Michael Zbinovec, a pharmaceutical analyst at Fitch Ratings in Chicago.
  
  In the Atlantic City case, Humeston, a Purple Heart recipient, says he took the drug for pain in his knees, one of which he injured in Vietnam.

• 
  Fitch Rates Triad Hospitals, Inc. 'BB+/BB-' - [Cached Version]
  Published on: 7/30/2004    Last Visited: 7/30/2004  

  Contact: Fitch Ratings, Chicago Luke J. Coha, 312-606-2320 Mike Zbinovec, 312-368-3165 or Fitch Ratings, New York Brian Bertsch, 212-908-0549 (Media Relations)

• 
  Fitch Upgrades McKesson's IDR to 'BBB+'; Affirms... - [Cached Version]
  Published on: 9/29/2006    Last Visited: 9/29/2006  

  Contact:Fitch Ratings, Chicago Bob Kirby, +1-312-368-3147 Michael Zbinovec +1-312-368-3164 Media Relations, New York Sandro Scenga, +1-212-908-0278

• 
  Merck starts Vioxx defense - [Cached Version]
  Published on: 7/21/2005    Last Visited: 7/21/2005  

  "The industry watches large class actions-type lawsuits because you wonder if it is ever going to become a Wyeth scenario where the costs could balloon out of control," said Michael Zbinovec, director of corporate finance and a pharmaceutical analyst for Fitch Ratings in Chicago.
  
  "Costs from the fen-phen litigation are over $21.1 billion as far as the reserve, and I think the pharmaceutical industry learned from that.That is real money," he said.
  ...
  "The direct link to Vioxx is convoluted by the fact that cardiovascular events are so prevalent in the general population," Zbinovec said.
  
  Vioxx patients also tend to be older and have other illnesses like diabetes, obesity and high blood pressure, so linking the drug directly to patient death may be difficult.
  
  "The legal system only has the capacity to handle so many cases on an annual basis," Zbinovec said.
  
  "It definitely does not allow for these huge spikes and payouts from the company on an annual basis," he said.

• 
  Merck’s defense of Vioxx - [Cached Version]
  Published on: 7/17/2005    Last Visited: 6/15/2006  

  "The industry watches large class actions-type lawsuits because you wonder if it is ever going to become a Wyeth [fen-phen maker] scenario where the costs could balloon out of control," says Michael Zbinovec, director of corporate finance and a pharmaceutical analyst for Fitch Ratings in Chicago.

Page:  1 2